Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2010

01-02-2010 | Original Article

Histological Changes in Chinese Chronic Hepatitis B Patients with ALT Lower Than Two Times Upper Limits of Normal

Authors: En-Qiang Chen, Fei-Jun Huang, Ling-Li He, Lang Bai, Li-Chun Wang, Tao-You Zhou, Xue-Zhong Lei, Cong Liu, Hong Tang

Published in: Digestive Diseases and Sciences | Issue 2/2010

Login to get access

Abstract

The role of ALT as a predictor of liver injury has been questioned. The aim of this study is to use liver biopsy to assess the degree of liver injury in patients with chronic hepatitis B(CHB) whose ALT < 2 × upper limit of normal (ULN). A total of 49.2% of patients in this study had significant inflammation (grade ≥2) and 36.4% had significant fibrosis (stage ≥2). The frequency of serious inflammation and fibrosis was similar in patients with different ALT levels. The level of serum HBV DNA was not significantly associated with the extent of inflammation and fibrosis. Advanced age was a significant independent predictor of histological damage and the presence of more significant inflammation and fibrosis. We conclude that many CHB patients with ALT < 2 × ULN have significant liver inflammation or fibrosis and that liver biopsy is necessary to assess liver damage and should be used to assess the need for anti-viral therapy.
Literature
2.
go back to reference Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol. 2007;13:74–81.PubMed Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol. 2007;13:74–81.PubMed
5.
8.
9.
go back to reference Chinese Society of Hepatology, Chinese Medical Association. Chinese Society of Infectious Diseases, Chinese Medical Association: the guideline of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2005;13:881–891. Chinese Society of Hepatology, Chinese Medical Association. Chinese Society of Infectious Diseases, Chinese Medical Association: the guideline of prevention and treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2005;13:881–891.
12.
14.
go back to reference Nguyen MH, Trinh H, Garcia RT. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation (abstr 1008). Hepatology. 2005;42:A593. Nguyen MH, Trinh H, Garcia RT. Significant histologic disease in HBV-infected patients with normal to minimally elevated ALT levels at initial evaluation (abstr 1008). Hepatology. 2005;42:A593.
16.
go back to reference Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology. 1998;27:1213–1219. doi:10.1002/hep.510270505.CrossRefPubMed Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology. 1998;27:1213–1219. doi:10.​1002/​hep.​510270505.CrossRefPubMed
18.
go back to reference ter Borg F, ten Kate FJ, Cuypers HT, et al. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet. 1998;351:3085–3091. ter Borg F, ten Kate FJ, Cuypers HT, et al. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet. 1998;351:3085–3091.
21.
go back to reference Yuen MF, Sablon E, Yuan HJ, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis. 2002;186:1335–1338. doi:10.1086/344327.CrossRefPubMed Yuen MF, Sablon E, Yuan HJ, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis. 2002;186:1335–1338. doi:10.​1086/​344327.CrossRefPubMed
22.
go back to reference Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002;36:1408–1415.PubMed Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002;36:1408–1415.PubMed
24.
go back to reference Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–774.PubMed Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771–774.PubMed
26.
go back to reference Wang JS, Zhu QR. Interruption of the transmission of hepatitis B virus from mother to babies. Zhonghua Gan Zang Bing Za Zhi. 2002;10:308–310.PubMed Wang JS, Zhu QR. Interruption of the transmission of hepatitis B virus from mother to babies. Zhonghua Gan Zang Bing Za Zhi. 2002;10:308–310.PubMed
Metadata
Title
Histological Changes in Chinese Chronic Hepatitis B Patients with ALT Lower Than Two Times Upper Limits of Normal
Authors
En-Qiang Chen
Fei-Jun Huang
Ling-Li He
Lang Bai
Li-Chun Wang
Tao-You Zhou
Xue-Zhong Lei
Cong Liu
Hong Tang
Publication date
01-02-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0724-5

Other articles of this Issue 2/2010

Digestive Diseases and Sciences 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine